Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Optimizing Clinical Trial Eligibility Design Using Natural Language Processing Models and Real-World Data: Algorithm Development and Validation

View through CrossRef
Background Clinical trials are vital for developing new therapies but can also delay drug development. Efficient trial data management, optimized trial protocol, and accurate patient identification are critical for reducing trial timelines. Natural language processing (NLP) has the potential to achieve these objectives. Objective This study aims to assess the feasibility of using data-driven approaches to optimize clinical trial protocol design and identify eligible patients. This involves creating a comprehensive eligibility criteria knowledge base integrated within electronic health records using deep learning–based NLP techniques. Methods We obtained data of 3281 industry-sponsored phase 2 or 3 interventional clinical trials recruiting patients with non–small cell lung cancer, prostate cancer, breast cancer, multiple myeloma, ulcerative colitis, and Crohn disease from ClinicalTrials.gov, spanning the period between 2013 and 2020. A customized bidirectional long short-term memory– and conditional random field–based NLP pipeline was used to extract all eligibility criteria attributes and convert hypernym concepts into computable hyponyms along with their corresponding values. To illustrate the simulation of clinical trial design for optimization purposes, we selected a subset of patients with non–small cell lung cancer (n=2775), curated from the Mount Sinai Health System, as a pilot study. Results We manually annotated the clinical trial eligibility corpus (485/3281, 14.78% trials) and constructed an eligibility criteria–specific ontology. Our customized NLP pipeline, developed based on the eligibility criteria–specific ontology that we created through manual annotation, achieved high precision (0.91, range 0.67-1.00) and recall (0.79, range 0.50-1) scores, as well as a high F1-score (0.83, range 0.67-1), enabling the efficient extraction of granular criteria entities and relevant attributes from 3281 clinical trials. A standardized eligibility criteria knowledge base, compatible with electronic health records, was developed by transforming hypernym concepts into machine-interpretable hyponyms along with their corresponding values. In addition, an interface prototype demonstrated the practicality of leveraging real-world data for optimizing clinical trial protocols and identifying eligible patients. Conclusions Our customized NLP pipeline successfully generated a standardized eligibility criteria knowledge base by transforming hypernym criteria into machine-readable hyponyms along with their corresponding values. A prototype interface integrating real-world patient information allows us to assess the impact of each eligibility criterion on the number of patients eligible for the trial. Leveraging NLP and real-world data in a data-driven approach holds promise for streamlining the overall clinical trial process, optimizing processes, and improving efficiency in patient identification.
Title: Optimizing Clinical Trial Eligibility Design Using Natural Language Processing Models and Real-World Data: Algorithm Development and Validation
Description:
Background Clinical trials are vital for developing new therapies but can also delay drug development.
Efficient trial data management, optimized trial protocol, and accurate patient identification are critical for reducing trial timelines.
Natural language processing (NLP) has the potential to achieve these objectives.
Objective This study aims to assess the feasibility of using data-driven approaches to optimize clinical trial protocol design and identify eligible patients.
This involves creating a comprehensive eligibility criteria knowledge base integrated within electronic health records using deep learning–based NLP techniques.
Methods We obtained data of 3281 industry-sponsored phase 2 or 3 interventional clinical trials recruiting patients with non–small cell lung cancer, prostate cancer, breast cancer, multiple myeloma, ulcerative colitis, and Crohn disease from ClinicalTrials.
gov, spanning the period between 2013 and 2020.
A customized bidirectional long short-term memory– and conditional random field–based NLP pipeline was used to extract all eligibility criteria attributes and convert hypernym concepts into computable hyponyms along with their corresponding values.
To illustrate the simulation of clinical trial design for optimization purposes, we selected a subset of patients with non–small cell lung cancer (n=2775), curated from the Mount Sinai Health System, as a pilot study.
Results We manually annotated the clinical trial eligibility corpus (485/3281, 14.
78% trials) and constructed an eligibility criteria–specific ontology.
Our customized NLP pipeline, developed based on the eligibility criteria–specific ontology that we created through manual annotation, achieved high precision (0.
91, range 0.
67-1.
00) and recall (0.
79, range 0.
50-1) scores, as well as a high F1-score (0.
83, range 0.
67-1), enabling the efficient extraction of granular criteria entities and relevant attributes from 3281 clinical trials.
A standardized eligibility criteria knowledge base, compatible with electronic health records, was developed by transforming hypernym concepts into machine-interpretable hyponyms along with their corresponding values.
In addition, an interface prototype demonstrated the practicality of leveraging real-world data for optimizing clinical trial protocols and identifying eligible patients.
Conclusions Our customized NLP pipeline successfully generated a standardized eligibility criteria knowledge base by transforming hypernym criteria into machine-readable hyponyms along with their corresponding values.
A prototype interface integrating real-world patient information allows us to assess the impact of each eligibility criterion on the number of patients eligible for the trial.
Leveraging NLP and real-world data in a data-driven approach holds promise for streamlining the overall clinical trial process, optimizing processes, and improving efficiency in patient identification.

Related Results

Hubungan Perilaku Pola Makan dengan Kejadian Anak Obesitas
Hubungan Perilaku Pola Makan dengan Kejadian Anak Obesitas
<p><em><span style="font-size: 11.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-langua...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Design
Design
Conventional definitions of design rarely capture its reach into our everyday lives. The Design Council, for example, estimates that more than 2.5 million people use design-related...
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...
Validation in Doctoral Education: Exploring PhD Students’ Perceptions of Belonging to Scaffold Doctoral Identity Work
Validation in Doctoral Education: Exploring PhD Students’ Perceptions of Belonging to Scaffold Doctoral Identity Work
Aim/Purpose: The aim of this article is to make a case of the role of validation in doctoral education. The purpose is to detail findings from three studies which explore PhD stude...
International Breast Cancer Study Group (IBCSG)
International Breast Cancer Study Group (IBCSG)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Breast Cancer Study Group (IBCSG). Clinical tria...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...

Back to Top